Global PEGylation Proteins Technology Market Growth (Status and Outlook) 2023-2029

Global PEGylation Proteins Technology Market Growth (Status and Outlook) 2023-2029

The global PEGylation Proteins Technology market size is projected to grow from US$ 1703.1 million in 2022 to US$ 3616.9 million in 2029; it is expected to grow at a CAGR of 11.4% from 2023 to 2029.

United States market for PEGylation Proteins Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for PEGylation Proteins Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for PEGylation Proteins Technology is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key PEGylation Proteins Technology players cover Abcam Plc., Aurigene Pharmaceutical Services Ltd., BroadPharm, Creative PEGworks, Celares GmbH, Creative Diagnostics, Enzon Pharmaceuticals, Inc., Laysan Bio, Inc. and Merck KGaA, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

Poly(ethylene glycol) (PEG) is a widely used polymer in drug delivery systems and is often directly conjugated to a drug therapeutic. PEG is a water-soluble, biologically inert, non-immunogenic synthetic polymer consisted of ethylene glycol (-CH2-CH2-O-) in repeating units. PEG is produced by anionic polymerization of ethylene oxide initiated by a nucleophilic attack of a methoxide ion on the epoxide ring. PEGylation of a protein conjugate is the process by which PEG is either non-covalently or covalently attached to a potential protein, peptide or antibody of interest to produce alterations in the physiochemical properties of the macromolecule in areas like conformation, electrostatic binding and hydrophobicity. PEGylation is used as a strategy to overcome challenges such as instability, inadequate circulation half-life and immunogenicity of a drug candidate intended for a therapeutic use.

LPI (LP Information)' newest research report, the “PEGylation Proteins Technology Industry Forecast” looks at past sales and reviews total world PEGylation Proteins Technology sales in 2022, providing a comprehensive analysis by region and market sector of projected PEGylation Proteins Technology sales for 2023 through 2029. With PEGylation Proteins Technology sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PEGylation Proteins Technology industry.

This Insight Report provides a comprehensive analysis of the global PEGylation Proteins Technology landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PEGylation Proteins Technology portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PEGylation Proteins Technology market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PEGylation Proteins Technology and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PEGylation Proteins Technology.

This report presents a comprehensive overview, market shares, and growth opportunities of PEGylation Proteins Technology market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type
Colony-stimulating Factor
Interferons
Erythropoietin
Recombinant Factor VII
Others

Segmentation by application
Pharmaceutical & Biotechnology Companies
Contract Research Organizations (CROs)
Academic & Research Institutes

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Abcam Plc.
Aurigene Pharmaceutical Services Ltd.
BroadPharm
Creative PEGworks
Celares GmbH
Creative Diagnostics
Enzon Pharmaceuticals, Inc.
Laysan Bio, Inc.
Merck KGaA
NOF America Corp.
Pfizer
Profacgen
Thermo Fisher Scientific, Inc.

Please note: The report will take approximately 2 business days to prepare and deliver.